Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print Cited Medium: Print ISSN: 0168-8278 (Print) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE
    • Publication Information:
      Publication: 2001- : Amsterdam : Elsevier
      Original Publication: Copehnagen : Munksgaard International Publishers, [c1984-
    • Subject Terms:
      Antiviral Agents/*therapeutic use ; HIV Infections/*complications ; Hepatitis D, Chronic/*complications ; Hepatitis D, Chronic/*drug therapy ; Interferon-alpha/*therapeutic use; Adult ; Alanine Transaminase/blood ; Biopsy ; Female ; Hepatitis Antibodies/blood ; Hepatitis B/complications ; Hepatitis C/complications ; Hepatitis D, Chronic/pathology ; Humans ; Interferon alpha-2 ; Male ; Recombinant Proteins ; Remission Induction
    • Abstract:
      Background/aims: Hepatitis delta virus (HDV) coinfection is frequent in patients infected with human immunodeficiency virus (HIV), and it may cause death independently of the development of full-blown AIDS. In order to evaluate the efficacy and tolerability of interferon alpha in the treatment of hepatitis delta in HIV-infected patients, and to compare them with those observed in anti-HIV-seronegative patients, we carried out an open uncontrolled trial on 21 HIV-uninfected and 16 HIV-infected patients without severe immunodeficiency.
      Methods: All patients were treated with recombinant interferon alpha 2b (IFN) at doses of 10 million units thrice weekly for 6 months, and 6 million units thrice weekly for an additional 6 months. Patients showing alanine transaminase activity values persistently reduced by at least 50% from basal values received an additional 1-year course of 3 million units thrice weekly.
      Results: Alanine aminotransferase normalization was observed in 19% of HIV-infected and 14% of HIV-uninfected subjects during the first year; in 12% of HIV-infected and in 9% of HIV-uninfected patients during the second year. Twenty-five percent of HIV-infected and 14% of HIV-uninfected patients stopped IFN because of poor compliance or side effects. Two years after stopping interferon treatment, one anti-HIV-seropositive and two anti-HIV-seronegative patients showed complete persistent biochemical, virological and histologic remission.
      Conclusions: Long-term efficacy and toxicity of IFN treatment seem not to be different in HIV-infected and -uninfected patients with delta hepatitis; given the overall poor rate of long-term response, IFN treatment could be considered only in immunocompetent HIV-HDV-coinfected patients, strictly selected because of rapidly evolving liver disease.
    • Accession Number:
      0 (Antiviral Agents)
      0 (Hepatitis Antibodies)
      0 (Interferon alpha-2)
      0 (Interferon-alpha)
      0 (Recombinant Proteins)
      EC 2.6.1.2 (Alanine Transaminase)
    • Publication Date:
      Date Created: 19980808 Date Completed: 19980929 Latest Revision: 20190817
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/s0168-8278(98)80177-3
    • Accession Number:
      9696491